Helicobacter pylori exposure could be associated with approximately 22% of colorectal cancer cases worldwide.
|Articles|June 24, 2022
Daily Medication Pearl: Capecitabine (Xeloda)
Author(s)Saro Arakelians, PharmD
Capecitabine (Xeloda) is indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.
Advertisement
Medication Pearl of the Day: Capecitabine (Xeloda)
Indication: Capecitabine (Xeloda) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.
Insight:
- Dosing: Monotherapy 1250 mg/m2 twice daily orally for 2 weeks followed by a 1-week rest period in 3-week cycles.
- Dosage forms: Tablets 150 mg and 500 mg.
- Adverse events: Most common adverse reactions (≥30%) were diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia. Other adverse reactions, including serious adverse reactions, have been reported
- Mechanism of action: Enzymes convert capecitabine to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2’-deoxyuridine monophosphate and 5-fluorouridine triphosphate. These metabolites cause cell injury by 2 different mechanisms.
Source:
Advertisement
Related to this article
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
4
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
5